Clinical trial
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular…
NCT00220805 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00220805 |
|---|---|
| Title | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration |
| Official title | Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-C, 10% Treatment in Subjects With Pure Occult Choroidal Neovascularization Due to Age Related Macular Degeneration |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP) |
| Enrollment | 96 |
| Start date | Jan 1, 2004 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 21, 2016 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: